Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Orion Office REIT Inc (ONL) Price & Performance

Heron Therapeutics IncTrade
Orion Office REIT IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Orion Office REIT Inc — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Orion Office REIT Inc trades at $2.65 (market cap $150.60M). The key difference: Orion Office REIT Inc is the larger of the two by market cap, and Orion Office REIT Inc pays a 3.02% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXONL
Market Cap
$91.46M$150.60M
Sector
HealthReal Estate
52-Week High
$1.96$3.04
52-Week Low
$0.39$1.93
Enterprise Value
$189.36M$634.25M
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.

Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.

Orion Office REIT Inc

ONL trades at $2.67, up 1.52% with mixed technical signals showing bullish oscillators but bearish moving averages. The company faces significant fundamental challenges with revenue declining from $208M in 2022 to $147.65M in 2025 and deep net losses widening to -$139.31M. However, strategic reviews with Wells Fargo and JPMorgan and recent refinancing extensions provide some stability amid ongoing portfolio repositioning toward dedicated use assets.

The outlook remains challenging with persistent losses and declining revenue, though the strategic review and deleveraging progress offer potential catalysts. Key risks include execution of asset sales, office market headwinds, and negative cash flow from operations. Analyst sentiment is divided with 50% buy and 50% hold ratings, reflecting uncertainty about the turnaround strategy's success.

Returns comparison

Trailing returns across standard periods

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Orion Office REIT Inc

Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.

Read more on ONL